Kallyope Presents Phase 2b Data on Elismetrep, a Novel Migraine Therapy, at the American Academy of Neurology Annual Meeting
Kallyope, a late-stage biopharmaceutical company focused on developing innovative treatments for neurological and metabolic disorders, has announced promising results from a Phase 2b clinical study evaluating elismetrep, a novel investigational therapy for the acute treatment of migraine. The findings were presented during an oral session titled “TRPM8 Antagonism with Elismetrep: A Novel Approach for Treating Migraine” at the American Academy of Neurology Annual Meeting 2026, currently taking place in Chicago.
The results mark an important milestone in migraine research, highlighting a potential first-in-class therapeutic approach targeting the transient receptor potential melastatin 8 (TRPM8) ion channel. Elismetrep is currently the only known TRPM8 antagonist in late-stage clinical development for migraine, positioning it as a potentially transformative treatment option for millions of patients worldwide who continue to struggle with inadequate symptom relief.
A significant unmet need in migraine care
Migraine is a highly prevalent and disabling neurological condition affecting hundreds of millions of people globally. Characterized by recurrent attacks of severe, throbbing head pain, often accompanied by nausea, vomiting, and sensitivity to light and sound, migraine can significantly disrupt daily life. For many patients, attacks are unpredictable and debilitating, forcing them to halt work, social activities, and personal responsibilities without warning.
Despite the availability of several classes of acute and preventive therapies—including triptans, CGRP inhibitors, and other analgesics—a substantial proportion of patients remain dissatisfied with current treatment options. Many individuals experience inconsistent efficacy, delayed onset of relief, or intolerable side effects, leading them to cycle through multiple medications in search of effective management.
According to Peter J. Goadsby, MD, PhD, a leading expert in headache disorders, elismetrep represents a potentially groundbreaking advance. He noted that by targeting a previously unaddressed biological pathway in migraine pathophysiology, the therapy could introduce an entirely new class of medicines—TRPM8 migraine-associated channel blockers (MACBs)—offering hope to patients who have not achieved adequate relief with existing treatments.
Phase 2b study design and methodology
The Phase 2b study (NCT06848075) was a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of elismetrep across multiple dose levels. A total of 431 participants were enrolled, with 398 ultimately treating a qualifying migraine attack during the study period.
Participants were adults experiencing between two and ten migraine attacks per month, representing a population with moderate disease burden. The study population had a mean age of 46 years, and the majority of participants (87%) were female, reflecting the higher prevalence of migraine in women. Notably, 35% of participants were already using preventive migraine therapies, and 31% were classified as triptan-resistant, indicating a population with significant unmet treatment needs.
Patients were randomized in a 2:1:2:2:1 ratio to receive either placebo or one of four doses of elismetrep (2 mg, 5 mg, 10 mg, or 20 mg) to treat a single migraine attack of moderate to severe intensity. Randomization was stratified based on the use of preventive medications to ensure balanced representation across treatment arms.
Efficacy endpoints were assessed at two hours post-dose, a standard timepoint in migraine clinical trials. The primary endpoint was pain freedom at two hours, while secondary endpoints included freedom from the most bothersome symptom (such as nausea or photophobia) and overall pain relief. Data were primarily collected through a patient-reported electronic diary (e-Diary), with supplemental interview data used to capture missing entries in a pre-specified supporting analysis.
Efficacy results demonstrate dose-dependent benefits
The study demonstrated clear dose- and time-dependent efficacy, with the 20 mg dose of elismetrep producing the most robust clinical effects across multiple endpoints.
In the primary analysis using e-Diary data בלבד, 17.6% of patients receiving the 20 mg dose achieved complete pain freedom at two hours, compared to 9.1% in the placebo group. While this result approached statistical significance (odds ratio [OR]=2.1, P=0.0650), a pre-specified supporting analysis incorporating all available data showed a higher response rate of 19.6% versus 9.1% for placebo, achieving nominal statistical significance (OR=2.4, P=0.0344).
Secondary endpoints further reinforced the therapeutic potential of elismetrep. For freedom from the most bothersome symptom at two hours, 38.3% of patients in the 20 mg group achieved this outcome, compared to 24.2% in the placebo arm (OR=1.9, P=0.0425). Similarly, pain relief at two hours was reported by 58.8% of patients receiving the 20 mg dose, compared to 42.4% of those receiving placebo (OR=1.9, P=0.0293).
These findings suggest that elismetrep not only reduces pain intensity but also addresses associated symptoms that contribute significantly to the overall burden of migraine attacks.
Favorable safety and tolerability profile
In addition to its efficacy, elismetrep demonstrated a generally favorable safety profile in the Phase 2b study. No serious adverse events were reported, an encouraging outcome for a therapy intended for widespread use in acute migraine treatment.
The incidence of adverse events was dose-dependent, with most events in the 20 mg group classified as mild (70%) or moderate in severity. The most commonly reported side effects included oral paresthesia (9.8%), a sensation of warmth or feeling hot (9.8%), paresthesia (7.8%), hot flush (7.8%), and flushing (5.9%). These side effects were generally transient and manageable, suggesting an acceptable tolerability profile for further clinical development.
Advancing toward registrational trials
Brett Lauring, MD, PhD, Chief Medical Officer of Kallyope, described the Phase 2b results as highly encouraging, particularly in light of the limited effectiveness of current migraine therapies for many patients. He emphasized that only about 30% of migraine sufferers achieve consistent and adequate relief with existing treatments, underscoring the urgent need for new therapeutic options.
Lauring noted that by targeting a novel mechanism within the migraine cascade, elismetrep has the potential to provide a safe and effective alternative for patients who have not benefited from current therapies. Based on the strength of the data, Kallyope plans to initiate registrational trials for elismetrep in mid-2026, marking the next critical step toward potential regulatory approval.
Next-generation formulation to enhance performance
In parallel with its clinical development efforts, Kallyope has also developed an improved formulation of elismetrep designed to enhance its pharmacokinetic profile. The new liquid-filled softgel capsule (LSGC) formulation allows for more rapid absorption compared to the formulation used in the Phase 2b study.
This advancement is expected to result in a faster onset of action, a key consideration in acute migraine treatment where rapid relief is highly valued by patients. Additionally, improved absorption may enhance efficacy at the two-hour timepoint, which serves as the primary endpoint in registrational trials.
Kallyope has indicated that full pharmacokinetic data for the LSGC formulation will be presented at a future medical meeting in 2026, providing further insight into its potential advantages.
A promising future for migraine innovation
Jay Galeota, Chief Executive Officer and President of Kallyope, emphasized the broader significance of the elismetrep program. He highlighted the opportunity to bring a novel treatment option to millions of individuals affected by migraine, many of whom continue to experience debilitating symptoms despite available therapies.
Galeota reaffirmed the company’s commitment to advancing elismetrep as rapidly as possible, with the goal of delivering a meaningful new medicine to patients in need. If successful in later-stage trials, elismetrep could represent a major step forward in migraine care, introducing a new class of therapeutics and expanding the range of options available to patients and clinicians.
The Phase 2b results for elismetrep underscore the potential of targeting TRPM8 channels as a novel approach to migraine treatment. With demonstrated efficacy, a favorable safety profile, and ongoing advancements in formulation, the therapy is well positioned to progress into late-stage development.
As Kallyope prepares to launch registrational trials, the field of migraine therapeutics may be on the cusp of a significant innovation—one that could redefine treatment paradigms and improve quality of life for millions of patients worldwide.
About Transient Receptor Potential Melastatin 8 (TRPM8)
Migraine is increasingly understood as a disorder of trigeminal sensory neuron hyperexcitability, in which trigeminal sensory pathways become sensitized, leading to sensory hypersensitivity and amplified pain signaling. TRPM8 is a polymodal sensory ion channel expressed on a distinct subset of trigeminal sensory neurons relevant to migraine pain signaling, migraine-associated channels. In the context of migraine, TRPM8 activity is associated with trigeminal sensory neuron pathway activation, contributing to pain onset and heightened, sustained pain signaling.
TRPM8 is a mechanistically distinct therapeutic target from current migraine treatments, including calcitonin gene-related peptide (CGRP) receptor antagonists and serotonergic (5-HT)-based agents, and is the only TRP channel with an established genetic association to migraine in genome-wide association studies.
About Elismetrep
Elismetrep (K-304) is an investigational, novel, oral, TRPM8 migraine-associated channel blocker (MACB) that is highly selective for TRPM8 migraine-associated channels versus other TRP channels. Specifically designed to block TRPM8 activity, elismetrep has been shown to reduce migraine pain and associated symptoms.
The Phase 2b dose-ranging and proof of concept trial for elismetrep for the acute treatment of migraine in adults demonstrated clinically meaningful efficacy that is competitive with the current leading marketed therapies. Registrational trials for elismetrep for the acute treatment of migraine are planned to initiate by mid-2026. Elismetrep is an investigational product and has not been approved by the FDA or any other regulatory agency.
About Kallyope
Kallyope is a late-stage biotechnology company focused on developing innovative migraine and metabolic therapies for health challenges faced by hundreds of millions of people globally. Kallyope’s lead programs target previously unknown drivers of disease in neural signaling pathways. The Company’s most advanced candidate, elismetrep (K-304), is poised to begin registrational trials for the acute treatment of migraine in mid-2026.
The metabolism pipeline includes agents that target a novel target identified and validated by the Company’s Klarity™ platform, as well as oral small molecule approaches to the highly validated amylin pathway for the treatment of obesity. Kallyope was founded by world-leading neuroscientists and continues to explore the role of neural circuits in driving disease.
Source Link:https://www.businesswire.com/
